Ipsen Pharma

Ipsen Pharma Overview

Company Headquarters: Paris, France

Founded: 1929

Workforce: ~ 5,400+

Company Working:

Ipsen Pharma is a global pharmaceutical company operating in two segments, namely, specialty care and consumer healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rare disease areas. In the neuroscience segment, the company provides products for the treatment of cervical dystonia, adult spasticity, blepharospasm, hemifacial spasm, hyperhidrosis, and pediatric lower limb spasticity. Ipsen Pharma operates as a subsidiary of Mayroy S.A. The company has R&D centers and manufacturing sites located in China, France, Ireland, the UK, and the US. Ipsen Pharma is present in more than 115 countries and has a direct presence through corporates offices in around 35 countries across the globe.

Strategy

Ipsen Pharma is seeking to establish as a global biopharma company focused on innovation and specialty care that delivers differentiated therapeutics to meet unmet patient needs. Ipsen strategizes to look forward to innovative and sustainable growth in the near future. Additionally, the company concentrates on strategic collaboration and agreements for the expansion of its business.

Company Snapshot

$1,540M

Revenue

5,400

Employees

1929

Founded

Paris, France

Headquarters

SWOT Analysis

Strengths

Strong partnerships with key players
Robust research capabilities
Constitutes a large number of clinical trial candidates
Development and manufacturing of innovative drugs
High specialized research department
Focus on unmet needs of patients
With botulinum toxin type A Dysport, Ipsen offer a single product to treat a range of therapeutic indications
Well-developed R&D to boost manufacturing of a new generation of recombinant neurotoxins
Company has its direct commercial presence in over 30 countries worldwide which strengthens its market position

Weaknesses

Limited focus on Asian countries
Limited presence in the global market
Highly dependent on one market for revenue generation
Low presence in emerging markets can affect overseas trade
Overdependency on the European market for revenue generation appears to have adverse longer-term consequences for economic growth and development

Opportunities

Customer engagement campaigns
Collaborations with international partners
Strong product pipeline
Engaging in mergers and acquisitions
Strategic collaborations with other pharmaceutical companies, physicians and dermatologists to boost R&D
Building a pipeline of innovative products in botulinum toxin industry to gain maximum market share

Threats

High level of competition by strong players in the market
Highly competitive market
Stringent government policies
Fluctuations in demand hampers quality of product
High competition in the botulinum toxin market from other players can affect the company’s market share
Risks related to Intellectual Property Rights which could have a material impact on company’s business

Key Developments

Date	Approach	Development
–	Partnership	Ipsen Pharma and Galderma entered into an exclusive partnership, wherein Galderma acquired the exclusive rights to develop, promote, and distribute Dysport for aesthetic indications in the Asia-Pacific countries.
September 2019	Product Approval	Ipsen Pharma received FDA approval for Dysport (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients of age group 2 to 17. This approval is expected to boost the sales of botulinum toxin.

Product Offering

Ipsen Pharma
- Dysport

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.